Prelude Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-25,181
| Closed | -$23.3K | – | 968 |
|
|
2023
Q2 | $23.3K | Buy |
+25,181
| New | +$23.3K | ﹤0.01% | 890 |
|
|
2019
Q3 | – | Sell |
-2,204
| Closed | -$9K | – | 1152 |
|
|
2019
Q2 | $9K | Buy |
2,204
+1,385
| +169% | +$5.66K | ﹤0.01% | 1028 |
|
|
2019
Q1 | $4K | Sell |
819
-98
| -11% | -$479 | ﹤0.01% | 1255 |
|
|
2018
Q4 | $5K | Sell |
917
-51,842
| -98% | -$283K | ﹤0.01% | 1249 |
|
|
2018
Q3 | $715K | Sell |
52,759
-139
| -0.3% | -$1.88K | 0.04% | 281 |
|
|
2018
Q2 | $628K | Sell |
52,898
-46,796
| -47% | -$556K | 0.04% | 354 |
|
|
2018
Q1 | $1.12M | Buy |
99,694
+40,841
| +69% | +$459K | 0.08% | 209 |
|
|
2017
Q4 | $393K | Buy |
58,853
+14,294
| +32% | +$95.5K | 0.03% | 419 |
|
|
2017
Q3 | $365K | Sell |
44,559
-53,624
| -55% | -$439K | 0.03% | 406 |
|
|
2017
Q2 | $441K | Buy |
98,183
+78,677
| +403% | +$353K | 0.04% | 312 |
|
|
2017
Q1 | $107K | Buy |
+19,506
| New | +$107K | 0.01% | 717 |
|
|
2016
Q2 | – | Sell |
-24,900
| Closed | -$202K | – | 1492 |
|
|
2016
Q1 | $202K | Buy |
+24,900
| New | +$202K | 0.03% | 489 |
|